App-Quantinova.ai

A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry

Amy R. MacQueen - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Targeting the ERK5 and ERK1/2 pathways simultaneously induces mesenchymal to epithelial transition in TNBC

Akshita Bhatt - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Doxorubicin

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

Jayakumar Vadakekolathu - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Flotetuzumab

Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)

Karthick Vishwanathan - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Tagrisso

Hyperplexed immunofluorescence analysis (Cell DIVETM) of immune-related tumor heterogeneity in stage III colorectal cancer

Xanthi Stachtea - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin, 5-fluorouracil and folic acid

Optimizing dual immuno-oncology combinations with a virtual tumor

Fernando Ortega - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

a first-in-human pilot study

Daniel Breadner - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

MicroRNA deregulation of the serine synthesis pathway controls intrinsic and non-cell autonomous mechanism of resistance to Regorafenib in metastatic colorectal cancer (mCRC)

Somaieh Hedayat - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Regorafenib

Targeting N-myristoylation in B-cell lymphomas as a therapeutic strategy

Erwan Beauchamp - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

Ibrutinib

Characterising the in vivo response of lung tumors to KrasG12C inhibition

Carla P. Martins - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Developing sensitive assays to facilitate hit identification of RNA modifying enzymes

Chris Tomlinson - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Obesity

Ademetionine

TEAD inhibition reduces tumor proliferation in Merlin null meningioma and schwannoma

Liyam Laraba - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

Manidipine+delapril

A translational immuno-oncology platform to model T cell activation and Tex recovery in the tumor microenvironment

Robert Nunan - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon Gamma

The role of YAP signaling in KRAS driven non-small cell lung cancer

Marina Keil - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Mandy Lawson - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

PBRM1 defects are synthetic lethal with PARP and ATR inhibitors

Roman Merial Chabanon - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Methadone hydrochloride

Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease

Giovanni Marsico - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Investigating tumor intrinsic PD-1/PD-L1 signaling in canine osteosarcoma cell lines as a spontaneous model for human disease

Dziubek Katarzyna - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Osteosarcoma

N/A

A high throughput screen of the novel immuno-oncology target HPK1 identifies a range of chemical starting points for the development of potent and selective inhibitors

Denise Swift - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An integrated in vitro and in vivo approach providing insights in immune modulation

Shilina Roman - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Rituximab

Filters

45280 Abstracts